Alteogen, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Novel ALPHA-1 Antitrypsin Variant, Preparation Method Thereof and Use Thereof (US 9,051,395) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Antibody specifically binding to FOLR1 and uses thereof (US 11,866,492) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,012,606 | In Vivo Half Life Increased Fusion Protein or Peptide Maintained by Sustained in Vivo Release, and Method for Increasng in Vivo Half-Life Using Same In force · High confidence | In force | High confidence | |
| US 9,051,395 | Novel ALPHA-1 Antitrypsin Variant, Preparation Method Thereof and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,814,782 | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,902,753 | Method of purifying a long-acting human growth hormone In force · From the USPTO record | In force | From the USPTO record | |
| US 9,982,032 | Stable liquid formulation of fusion protein with IgG Fc domain In force · From the USPTO record | In force | From the USPTO record | |
| US 12,090,210 | Antibody-drug conjugate comprising modified antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 11,414,476 | Method for Producing Fusion Protein Having Igg FC Domain In force · High confidence | In force | High confidence | |
| US 11,235,065 | Antibody-drug conjugate comprising modified antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 11,981,719 | Growth hormone receptor antagonists and fusion proteins thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,866,492 | Antibody specifically binding to FOLR1 and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 14: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 1 no status recorded